All questions
Safety: Leqvio (inclisiran) in hypercholesterolemia
3 questions · 2 sources
Safety questions that apply to every indication of Leqvio are on Leqvio (inclisiran), all indications: Safety.
Side effects
What are the most common side effects of Leqvio?
“The data in Table 1 are derived from 3 placebo-controlled trials that included 1,833 adults with
hypercholesterolemia treated with LEQVIO, including 1,682 exposed for 18 months (median treatment duration
of 77 weeks) [see Clinical Studies (14)]. The mean age of the population was 64 years, 32% of the population
were female, 92% were White, 6% were Black or African American, 1% were Asian, and < 1% were other
races; 6% identified as Hispanic or Latino ethnicity. At baseline, 12% of patients had a diagnosis of HeFH and
85% had clinical atherosclerotic cardiovascular disease (ASCVD).
Adverse reactions reported in at least 3% of LEQVIO-treated patients, and more frequently than in placebo-
treated patients, are shown in Table 1.
Table 1: Adverse Reactions Occurring in Greater Than or Equal to 3% of LEQVIO-treated Adults with
Hypercholesterolemia and More Frequently than with Placebo (Trials 1, 2, and 3)
Adverse Reactions
Placebo (N = 1,822)
%
LEQVIO (N = 1,833)
%
Injection site reactiona
2
8
Arthralgia
4
5
Bronchitis
3
4
aincludes related terms such as: injection site pain, erythema and rash” (opens the source at this quote in a new tab)
Note: Table 1 gives the placebo percentage before the LEQVIO percentage for each adverse reaction.
How many patients stopped Leqvio because of side effects?
Safety evidence
What did ORION-8 show about Leqvio's long-term safety?
Note: ORION-8 included patients from ORION-9, which the Prescribing Information describes as a trial in adults with HeFH.